

Docket No.: B45313

DECLARATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"VACCINE COMPOSITIONS COMPRISING L2 AND/OR L3 IMMUNOTYPE  
LIPOOLIGOSACCHARIDES FROM LGTB - NEISSERIA MINIGITIDIS"

the specification of which (check one)

☐ is attached hereto.

☒ was filed on PCT/EP2003/008568 as Serial No. 31 July 2003  
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

| Number    | Country       | Filing Date      | Priority Claimed |
|-----------|---------------|------------------|------------------|
| 0218036.2 | Great Britain | 02 August 2002   | YES              |
| 0218037.0 | Great Britain | 02 August 2002   | YES              |
| 0218035.4 | Great Britain | 02 August 2002   | YES              |
| 0218051.1 | Great Britain | 02 August 2002   | YES              |
| 0220197.8 | Great Britain | 30 August 2002   | YES              |
| 0220199.4 | Great Britain | 30 August 2002   | YES              |
| 0225524.8 | Great Britain | 01 November 2002 | YES              |
| 0225531.3 | Great Britain | 01 November 2002 | YES              |
| 0230164.6 | Great Britain | 24 December 2002 | YES              |
| 0230168.7 | Great Britain | 24 December 2002 | YES              |
| 0230170.3 | Great Britain | 24 December 2002 | YES              |
| 0305028.3 | Great Britain | 05 March 2003    | YES              |

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number      Filing Date

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section

112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

| Serial No. | Filing Date | Status |
|------------|-------------|--------|
|------------|-------------|--------|

Direct all correspondence to the address associated with Customer Number 20462.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00 Full Name of Inventor: Ralph BIEMANS

Inventor's Signature: 

Date: 22/02/2005

Residence: Rixensart, Belgium BEL

Citizenship: BELGIAN

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

2-00 Full Name of Inventor: Philippe DENOEL

Inventor's Signature: 


Date: 21/02/2005

Residence: Rixensart, Belgium BEL

Citizenship: BELGIAN

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

300 Full Name of Inventor: Christiane FERON

Inventor's Signature: 


Date: 22.02.2005

Residence: Rixensart, Belgium BEX

Citizenship: BELGIAN

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

400 Full Name of Inventor: Carine GORAJ

Inventor's Signature: 


Date: 22.02.2005

Residence: Rixensart, Belgium BEX

Citizenship: BELGIAN

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-093

500 Full Name of Inventor: Jan POOLMAN

Inventor's Signature: 

Date: feb 21 '05

Residence: Rixensart, Belgium BEX

Citizenship: DUTCH

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

6-00 Full Name of Inventor: Vincent WEYNANTS

Inventor's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Residence: Rixensart, Belgium

BEX

Citizenship: BELGIAN


Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

|  |  |
|--|--|
| <b>STATEMENT UNDER 37 CFR 3.73(b)</b>  |  |
| Applicant/Patent Owner: <b>GlaxoSmithKline Biologicals s.a.</b>  |  |
| International Application No./Patent No.: <b>PCT/EP2003/008568</b> Filed/Issue Date: <b>31 July 2003</b>   |  |
| Entitled: <b>VACCINE COMPOSITIONS COMPRISING L2 AND/OR L3 IMMUNOTYPE LIPOOLIGOSACCHARIDES FROM LGTB - NEISSERIA MINIGITIDIS</b>  |  |
| GlaxoSmithKline Biologicals s.a., a corporation, states that it is:  |  |
| 1. <input checked="" type="checkbox"/> the assignee of the entire right, title, and interest; or   |  |
| 2. <input type="checkbox"/> an assignee of less than the entire right, title and interest.<br>The extent (by percentage) of its ownership interest is _____ % in the patent application/patent identified above by virtue of either;   |  |
| A. <input type="checkbox"/> An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.  |  |
| OR   |  |
| B. <input type="checkbox"/> A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:  |  |
| 1. From: _____ To: _____<br>The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.  |  |
| 2. From: _____ To: _____<br>The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.  |  |
| 3. From: _____ To: _____<br>The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.  |  |
| <input type="checkbox"/> Additional documents in the chain of title are listed on a supplemental sheet.  |  |
| <input checked="" type="checkbox"/> Copies of assignments or other documents in the chain of title are attached.<br>[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08] |  |
| The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.  |  |
| <br>_____<br>Signature<br>_____<br>Marcus Jonathan William DALTON<br>Printed or Typed Name<br>_____<br>Attorney and Authorised Official<br>_____<br>Title   | _____<br><b>22 MAR 2005</b><br>Date<br>_____<br>+44 20 8047 4401<br>Telephone Number |

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

|   |                               |   |
|---|-------------------------------|---|
| <b>POWER OF ATTORNEY<br/>and<br/>CORRESPONDENCE ADDRESS<br/>INDICATION FORM</b> | <b>Application Number</b>     | PCT/EP2003/008568   |
|   | <b>Filing Date</b>            | 31 July 2003  |
|   | <b>First Named Inventor</b>   | Ralph BIEMANS   |
|   | <b>Title</b>                  | VACCINE COMPOSITIONS COMPRISING L2<br>AND/OR L3 IMMUNOTYPE<br>LIPOOLIGOSACCHARIDES FROM LGTB -<br>NEISSERIA MINIGITIDIS |
|   | <b>Art Unit</b>               |   |
|   | <b>Examiner Name</b>          |   |
|   | <b>Attorney Docket Number</b> | B45313  |

I hereby appoint:

☒ Practitioners associated with the Customer Numbers. 20462

Or

☐ Practitioner(s) named below:

| Name | Registration Number |
|------|---------------------|
|      |                     |

As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☐ The address associated with the above-mentioned Customer Number:

Or

☒ The address associated with Customer Number 20462

Or

☐ Firm or Individual Name:

|            |             |
|------------|-------------|
| Address:   |             |
| Address:   |             |
| City:      | State: Zip: |
| Country:   |             |
| Telephone: | Fax:        |

I am the:

☐ Applicant/Inventor:

☒ Assignee or record of the entire interest. See 37 CFR 3.71.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

**SIGNATURE of Applicant or Assignee of Record**

|  |                             |
|--|-----------------------------|
| Signature: <i>Marcus Jonathan William Dalton</i>   | Date: 22 MAR 2005           |
| Name: <b>Marcus Jonathan William DALTON</b>  | Telephone: +44 20 8047 4401 |
| Title and Company: <b>Attorney and Authorised Official, GlaxoSmithKline Biologicals s.a.</b> |                             |

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below\*.

☐ \*Total of: forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ASSIGNMENT

WHEREAS I/We, Ralph BIEMANS of Rixensart, Belgium, Philippe DENOEL of Rixensart, Belgium, Christiane FERON of Rixensart, Belgium, Carine GORAJ of Rixensart, Belgium, Jan POOLMAN of Rixensart, Belgium and Vincent WEYNANTS of Rixensart, Belgium have made an invention entitled:


VACCINE COMPOSITIONS COMPRISING L2 AND/OR L3 IMMUNOTYPE  
LIPOOLIGOSACCHARIDES FROM LGTB - NEISSERIA MINIGITIDIS

for which on February 21 & 22, 2005 I/we executed an application for Letters Patent of the United States of America;

NOW, THEREFORE, in return for valuable consideration paid to me/us by GlaxoSmithKline Biologicals s.a. of Rue de l'Institut 89, B-1330 Rixensart, Belgium (hereinafter "ASSIGNEE"), the receipt of which is hereby acknowledged and intending to be legally bound, I/we do hereby assign unto the said ASSIGNEE, its successors and assigns, the entire right, title and interest in and to the said invention, said executed application, any division, continuation and continuation-in-part of said application and reissue applications, and all Letters Patents of the United States of America to be obtained therefor;

I/we hereby covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment and sale;

In addition I/we agree to provide ASSIGNEE upon its request with all pertinent facts and documents relating to said invention, and said Letters Patent as may be known and accessible to me/us, and to testify as to the same in any interference or litigation related thereto, and to execute further instruments (including divisional, continuation, continuation-in-part or reissue applications, affidavits or other instruments) required to apply for, obtain, maintain and enforce said application and said Letters Patent which may be necessary; this agreement to be binding upon my/our heirs, executors and administrators.



Inventor 1  
Ralph BIEMANS

Date: 22/02/2005



Inventor 2  
Philippe DENOEL

Date: 22/02/2005




Inventor 3  
Christiane FERON

Date: 22/02/2005




Inventor 4  
Carine GORAJ

Date: 22.02.2005



Inventor 5  
Jan POOLMAN

Date: Feb 21 2005



Inventor 6  
Vincent WEYNANTS

Date: 21/02/2005